Table 1.
Patient characteristics
| Overall (N = 10) |
Stable disease (N = 4) |
Progressive disease (N = 6) |
|
|---|---|---|---|
| Age years median [range] | 63 [19–75] | 69 [19–75] | 60 [42–73] |
| Male N (%) | 4/10 (40%) | 1/4 (25%) | 3/6 (50%) |
| RET | |||
| Wild-type N (%) | 6/10 (60%) | 3/4 (75%) | 3/6 (50%) |
| Unknown N (%) | 4/10 (40%) | 1/4 (25%) | 3/6 (50%) |
| Disease extent | |||
| Moderate | 8/10 (80%) | 2/4 (50%) | 6/6 (100%) |
| Extensive | 2/10 (20%) | 2/4 (50%) | 0/6 (0%) |
| Tumormarkers | |||
| Calcitonin DT years, [range] | 2.4 [0.6–4.1] | 0.8 [0.6–4.1] | 2.6 [2.4–2.9] |
| CEA DT years, [range] | 1.9 [0.6–7.4] | 1.9 [1.2–2.1] | 4.0 [0.6–7.4] |
| PRRT indication | |||
| PD | 8/10 (70%) | 3/4 (75%) | 5/6 (83%) |
| Tumor localization❶ | 2/10 (30%) | 1/4 (25%) | 1/6 (17%) |
| WHO | |||
| 1 | 8/10 (80%) | 3/4 (75%) | 5/6 (83%) |
| 3 | 2/10 (20%) | 1/4 (25%) | 1/6 (17%) |
| Hormonal functioning ❷ | 3/10 (30%) | 1/4 (25%) | 2/6 (33%) |
| Endpoints | |||
| Death from MTC | 7/10 | 2/4 (50%) | 5/6 (83%) |
| Death other cause❸ | 1/10 | 1/4 (25%) | 0/4 (0%) |
| Alive | 2/10 | 1/4 (25%) | 1/4 (25%) |
Abbreviations: CEA, carcinoembryonic antigen; DT, doubling time; MTC, medullary thyroid carcinoma; N, number; PRRT, peptide receptor radionuclide therapy; RET, rearranged during transfection; WHO, world health organization performance status
Footnote:
❶ Intracardial metastasis and biochemical progression; inoperable cervical tumour load
❷ Ectopic ACTH; PTH-rp; dopamine
❸ Fibrosarcoma